Rituximab in Treating Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them.
PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody rituximab in
treating patients with multiple myeloma that is newly diagnosed.